Printer Friendly

Selected gene therapy for head and neck cancer may be feasible.

Findings from a tissue culture model of head and neck cancer suggest that gene therapy may be an effective treatment strategy.

Using a 3-dimensional tissue culture model of head and neck mucosa, researchers at the University of North Carolina in Chapel Hill found that adenoviruses are able to infect only the most undifferentiated cell layers. The more superficial differentiated layers act as a barrier to infection of underlying layers due to differing expression of the human coxsackie and adenovirus receptor (hCAR). Both normal basal epithelial cells and head and neck squamous cell carcinoma cells express high levels of hCAR, whereas differentiated epithelial cells have undetectable levels of the protein. Theoretically, in people at high risk for cancer, adenoviral gene therapy would infect only the precancerous cell, leaving normal, well-differentiated tissue alone. (Human Gene Therapy 2000;62:426-434.)
COPYRIGHT 2000 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:study by University of North Carolina in Chapel Hill
Comment:Selected gene therapy for head and neck cancer may be feasible.(study by University of North Carolina in Chapel Hill)
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Dec 15, 2000
Previous Article:Gene therapy steadies erratic heartbeat in pigs; potential treatment for human arrhythmias.
Next Article:Anti-CMV IgM titer predicts CMV disease after liver transplantation.

Related Articles
Targeted Genetics presents advances in systemic gene delivery technology.
New research finds cancer fighting compound in red wine.
AAAC honors nine scientists.
Introgen's mda-7 gene therapeutic receives patent.
Targeted Genetics expands patent portfolio for program.
Key patent obtained for Introgen's Phase 3 product.
Help instead of hype.
Cooperation achieves results at UNC-CH.
Polymorphisms modify breast cancer risk in smokers.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters